Aligos Therapeutics (ALGS) Other Non-Current Assets (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Other Non-Current Assets for 8 consecutive years, with $759000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Assets rose 18.59% year-over-year to $759000.0; the trailing twelve-month figure through Jun 2026 stood at $759000.0 (up 18.59% YoY), and the FY2025 full-year result was $715000.0, up 14.04% from the prior year.
• Other Non-Current Assets was little changed at $759000.0 in Q2 2026 per ALGS's latest filing, from $759000.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $1.6 million in Q1 2022 and bottomed at $21000.0 in Q2 2022.
• Historically, Other Non-Current Assets has averaged $595388.9 across 5 years, with a median of $631500.0 in 2024.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets tumbled 89.12% in 2022, then soared 1402.38% in 2024.
• Over 5 years, Other Non-Current Assets stood at $634000.0 in 2022, then slipped by 1.42% to $625000.0 in 2023, then increased by 0.32% to $627000.0 in 2024, then grew by 14.04% to $715000.0 in 2025, then advanced by 6.15% to $759000.0 in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $759000.0, $759000.0, and $715000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.